Search
Centanafadine
go.drugbank.com/drugs/DB14841ApprovedInvestigational[L63934] The FDA approved centanafadine on July 24, 2026, for the treatment of ADHD in adults and pediatric patients 6 years of age and older weighing at least 20 kg; use is not recommended below that … [L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSimvastatin
go.drugbank.com/drugs/DB00641ApprovedInvestigationalIt belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the … [A181409,A181535,A181538,A1793] Potency is thought to correlate to tissue permeability as the more lipophilic statins such as simvastatin are thought to enter endothelial cells by passive diffusion, as
Mixtures: EZETIMIBE E SIMVASTATINA EG, EZETIMIBE E SIMVASTATINA EGEstrone
go.drugbank.com/drugs/DB00655ApprovedEstrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase. … It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione.
Categories: Sex Hormones and Modulators of the Genital SystemHomatropine
go.drugbank.com/drugs/DB11181Approveduse has not been approved by the FDA to be safe and effective. … Homatropine hydrobromide has been administered as ophthalmic solutions as a cycloplegic to temporarily paralyze accomodation, and to induce mydriasis (the dilation of the pupil); however such therapeutic
Amlexanox
go.drugbank.com/drugs/DB01025ApprovedWithdrawnRecurrent aphthous ulcer (RAU) is the most prevalent oral mucosal disease in humans, estimated to affect between 5% and 50% of the general population.
Elinzanetant
go.drugbank.com/drugs/DB18968ApprovedInvestigational[L53798] Later the same year, it was approved in the US for the same indication. [L54216] … [A274198] On July 23, 2025, it was approved by Health Canada to treat moderate to severe vasomotor symptoms (VMS) associated with menopause.
Propylthiouracil
go.drugbank.com/drugs/DB00550ApprovedPropythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. … (From Martindale, The Extra Pharmacopeoia, 30th ed, p534)
Collagenase clostridium histolyticum
go.drugbank.com/drugs/DB00048ApprovedInvestigational[L14882] The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ulcers. … It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease.
Pioglitazone
go.drugbank.com/drugs/DB01132ApprovedInvestigationalPioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. … [L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in vivo_ with little consequence
Mixtures: PIOGLITAZONE E METFORMINA EG, PIOGLITAZONE E METFORMINA EGFexinidazole
go.drugbank.com/drugs/DB12265Approved[A237555, A237560] Fexinidazole received a positive opinion from the European Medicines Agency (EMA) in November 2018 and was approved by the FDA on July 16, 2021. … [A237550, A237560] Fexinidazole, which was originally developed in the 1970s/80s by Hoechst AG and subsequently rediscovered through the Drugs for Neglected Diseases Initiative (DNDi) in 2005, is the first